Sarilumab and Non-biologic Disease-Modifying Antirheumatic Drugs in Patients with Active RA and Inadequate Response or Intolerance to TNF Inhibitors
Arthritis Rheumatol 2016. DOI:10.1002/art.39944.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Rheumatol 2016. DOI:10.1002/art.39944.
Ann Rheum Dis 2016. DOI 10.1136/annrheumdis-2016-210310
Ann Rheum Dis 2016;75:1979–83
Arthritis Res Ther 2016; 18:211. DOI 10.1186/s13075-016-1108-9
Arthritis Res Ther 2016; 18:198. DOI.10.1186/s13075-016-9
Arthritis Care Res 2016; Accepted article. DOI 10.1002/acr.23004
Arthritis Care Res 2016; Accepted article. DOI 10.1002/acr.23008.
Ann Rheum Dis 2016;0:1–7 DOI 10.1136/annrheumdis-2016-209773.
Drug Saf. 2016 June 9; 39:755–762; DOI 10.1007/s40264-016-0431-z [Epub ahead of print]
Cochrane Database of Systematic Reviews 2016 Issue 5. Art. No.: CD012183 [DOI: 10.1002/14651858.CD012183].